When CEO and president at Bind Therapeutics, Andrew Hirsch had to swing the ax to his workforce, file for bankruptcy and in the end sell off its remaining assets to Pfizer.
− Proceeds to support Recursion’s development of its broad clinical-stage pipeline and expansion of the capabilities of its drug discovery platform − − Series D financing led by …
The Utah-based biotech company’s agreement with Bayer is potentially worth over $1 billion.
How do you propel science forward in between discoveries? Or when the lab is closed? How about when researchers are remote? You become your own research publishing platform. This ...
Flagship has provided more than $50 million to the developer of biological drugs.
While Covid-19 slowed the startup economy in the first half of 2020, the bioeconomy continued to power ahead. Fifty-six synthetic biology companies pulled in just over $3 billion of equity ...
Despite the pandemic, multibillion-dollar fortunes are still being minted in America. From Zoom founder Eric Yuan to biotech pioneer Alice Schwartz, meet the newest members of Forbes annual ...
From Forbes 400 members like Bill Gates to celebrities like Will Smith and Jada Pinkett Smith, here are the nation’s most influential impact investors.